IL-17 Inhibitors By Novartis, Lilly Don’t Show Suicide Signal, Firms Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s decision to withdraw from its collaboration with AstraZeneca to develop IL-17 inhibitor brodalumab for psoriasis due to concerns over suicide ideation has focused attention on the safety of other IL-17 agents.